Amneal Receives Approval for Leuprolide Acetate
Key injectable new product launch brings year-to-date injectables launches to 6.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for leuprolide acetate for injection.
Harsher Singh, SVP for Amneal Biosciences stated, “We are making tremendous progress expanding our injectables business. This latest new product is another key therapeutic for the institutional market and another complex, high value launch by the team.”
Leuprolide acetate injection is indicated in the palliative treatment of advanced prostatic cancer. For full prescribing information, see package insert located
According to IQVIA®, U.S. annual sales for this product for the 12 months ended September 2022 were $81 million.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit
SOURCE: Amneal Pharmaceuticals, Inc.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- NCPA Announces Keynote Speaker for Annual Convention
September 18th 2025
- Upcoming NCPA Items for Pharmacy Teams: September and October 2025
September 11th 2025
- NCPA Applauds FTC Pick for Associate Director of Health Care
September 10th 2025
- NCPA Leads Huge Coalition in Letter Asking Congress to Pass PBM Reform Act
September 8th 2025